Eli Lilly: positive trial results for muvalaplin in cardiology
(CercleFinance.com) - Eli Lilly announces positive results from a Phase 2 trial of muvalaplin, a selective oral inhibitor of lipoprotein(a) [Lp(a)], a genetic risk factor for cardiovascular disease.
The study demonstrated significant reductions in elevated Lp(a) levels at 12 weeks, with reductions of up to 85.8%, depending on dosage.
Muvalaplin also met its secondary endpoints, reducing apoB levels and enabling a majority of participants to reach target thresholds for Lp(a).
In addition, treatment-related adverse events were comparable between the muvalaplin and placebo groups, with no deaths reported.
We are very pleased with these promising results and look forward to exploring the next steps for muvalaplin, Lilly Research Laboratories said.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The study demonstrated significant reductions in elevated Lp(a) levels at 12 weeks, with reductions of up to 85.8%, depending on dosage.
Muvalaplin also met its secondary endpoints, reducing apoB levels and enabling a majority of participants to reach target thresholds for Lp(a).
In addition, treatment-related adverse events were comparable between the muvalaplin and placebo groups, with no deaths reported.
We are very pleased with these promising results and look forward to exploring the next steps for muvalaplin, Lilly Research Laboratories said.
Copyright (c) 2024 CercleFinance.com. All rights reserved.